IMFINZI® (Durvalumab)

The FDA on June 14, 2024, approved IMFINZI® with Carboplatin plus Paclitaxel followed by single-agent Durvalumab for adult patients with primary advanced or recurrent Endometrial cancer that is MisMatch Repair deficient (dMMR). IMFINZI® is a product of AstraZeneca UK Limited.